Title |
Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin
|
---|---|
Published in |
Journal of Translational Medicine, September 2014
|
DOI | 10.1186/s12967-014-0227-9 |
Pubmed ID | |
Authors |
David Fajardo-Ortiz, Luis Duran, Laura Moreno, Hector Ochoa, Victor M Castaño |
Abstract |
We explored how the knowledge translation and innovation processes are structured when theyresult in innovations, as in the case of liposomal doxorubicin research. In order to map the processes, a literature network analysis was made through Cytoscape and semantic analysis was performed by GOPubmed which is based in the controlled vocabularies MeSH (Medical Subject Headings) and GO (Gene Ontology). We found clusters related to different stages of the technological development (invention, innovation and imitation) and the knowledge translation process (preclinical, translational and clinical research), and we were able to map the historic emergence of Doxil as a paradigmatic nanodrug. This research could be a powerful methodological tool for decision-making and innovation management in drug delivery research. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 33% |
Mexico | 1 | 17% |
Germany | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 83% |
Scientists | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Ghana | 1 | 2% |
Unknown | 50 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 10 | 20% |
Researcher | 10 | 20% |
Student > Ph. D. Student | 7 | 14% |
Student > Bachelor | 4 | 8% |
Professor | 3 | 6% |
Other | 7 | 14% |
Unknown | 10 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 22% |
Engineering | 6 | 12% |
Agricultural and Biological Sciences | 3 | 6% |
Business, Management and Accounting | 3 | 6% |
Economics, Econometrics and Finance | 3 | 6% |
Other | 11 | 22% |
Unknown | 14 | 27% |